Posted by Michael Wonder on 29 Nov 2022
Health Canada has approved Sotyku (deucravacitinib tablets), an oral treatment for adults with moderate to severe plaque psoriasis
28 November 2022 - Sotyktu is the first and only approved TYK2 inhibitor in Canada and represents an important milestone in oral treatment for moderate to severe plaque psoriasis in nearly eight years.
Bristol Myers Squibb Canada today announced that Health Canada has approved Sotyku (deucravacitinib tablets), the first-in-its-class oral tablet for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
